BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
The trial showed that BMN 401 increased plasma PPi levels through week 52 versus the control group.
20 May 2026
20 May 2026
The trial showed that BMN 401 increased plasma PPi levels through week 52 versus the control group.
Hansa will receive €110m upfront and a further €5m once the European Medicines Agency accepts Idefirix’s full approval filing.
Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.